Literature DB >> 18377813

Alternative drug treatments for visceral leishmaniasis: miltefosine.

Mary E Wilson.   

Abstract

Entities:  

Year:  2008        PMID： 18377813

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN： 1523-3847            Impact factor:   3.725


× No keyword cloud information.
  8 in total

1.  Effect of highly active antiretroviral therapy on the incidence and clinical manifestations of visceral leishmaniasis in human immunodeficiency virus-infected patients.

Authors:  M J Fernández Cotarelo; J Abellán Martínez; J M Guerra Vales; P Martínez Sánchez; M Rodrigo Gómez De La Bárcena; E Salto Fernández
Journal:  Clin Infect Dis       Date:  2003-09-10       Impact factor: 9.079

2.  A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection.

Authors:  Koert Ritmeijer; Abren Dejenie; Yibeltal Assefa; Tadesse Beyene Hundie; Jo Mesure; Gerry Boots; Margriet den Boer; Robert N Davidson
Journal:  Clin Infect Dis       Date:  2006-06-20       Impact factor: 9.079

3.  Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani.

Authors:  R Lira; S Sundar; A Makharia; R Kenney; A Gam; E Saraiva; D Sacks
Journal:  J Infect Dis       Date:  1999-08       Impact factor: 5.226

4.  Relapses versus reinfections in patients coinfected with Leishmania infantum and human immunodeficiency virus type 1.

Authors:  Miguel A Morales; Israel Cruz; Jose M Rubio; Carmen Chicharro; Carmen Cañavate; Fernando Laguna; Jorge Alvar
Journal:  J Infect Dis       Date:  2002-04-22       Impact factor: 5.226

5.  Oral miltefosine for Indian visceral leishmaniasis.

Authors:  Shyam Sundar; T K Jha; C P Thakur; Juergen Engel; Herbert Sindermann; Christina Fischer; Klaus Junge; Anthony Bryceson; Jonathan Berman
Journal:  N Engl J Med       Date:  2002-11-28       Impact factor: 91.245

6.  Value of culture and nested polymerase chain reaction of blood in the prediction of relapses in patients co-infected with leishmania and human immunodeficiency virus.

Authors:  Cristina Riera; Roser Fisa; Esteban Ribera; Jaume Carrió; Vicenç Falcó; Montserrat Gállego; Lluis Moner; Israel Molina; Montserrat Portús
Journal:  Am J Trop Med Hyg       Date:  2005-12       Impact factor: 2.345

7.  Treatment of visceral leishmaniasis with injectable paromomycin (aminosidine). An open-label randomized phase-II clinical study.

Authors:  C P Thakur; T P Kanyok; A K Pandey; G P Sinha; C Messick; P Olliaro
Journal:  Trans R Soc Trop Med Hyg       Date:  2000 Jul-Aug       Impact factor: 2.184

8.  Visceral leishmaniasis in immunocompromised patients with and without AIDS: a comparison of clinical features and prognosis.

Authors:  Manuel L Fernández-Guerrero; Pablo Robles; Pablo Rivas; Francisca Mójer; Gemma Muñíz; Miguel de Górgolas
Journal:  Acta Trop       Date:  2004-03       Impact factor: 3.112
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.